AstraZeneca is strengthening its partnership with Immunai to use artificial intelligence in cancer drug development.
As part of the expanded multi-year agreement, Immunai could receive up to $37.5 million between 2026 and 2027.
The new deal extends the partnership between AstraZeneca and Immunai through 2027.
It also highlights the growing use of AI in drug research, especially for finding biomarkers, selecting the right patients for treatments, and studying how patients respond to therapies.
Under the agreement, AstraZeneca will continue using Immunai’s platform in its cancer research programs.
The platform will help the company discover biomarkers, identify the right patients for treatments, improve drug dosing, and better understand how treatments work.
“Across AstraZeneca, we are continuously investing in frontier AI models and solutions to inform clinical development decisions and derive novel mechanistically informed biomarkers,” said Jorge Reis-Filho, AstraZeneca’s Chief of AI for Science Innovation. “The expansion of this ongoing collaboration is a reflection of our conviction in the transformative potential of AI to improve patient outcomes.”
“The fact that AstraZeneca continues to deepen this collaboration is a strong signal for us that the platform is delivering,” Solomon said. “We are focused on generating insights that are mechanistically grounded and clinically relevant.”
Immunai was founded to better understand the human immune system using machine learning and single-cell genomics technology.
The company is now part of a growing group of AI-focused biotech firms that provide technology and research tools to pharmaceutical companies instead of developing drugs on their own.
Read More- Blunav raises $1 million round led by Piper Serica
